v3.26.3
SIGNIFICANT ACCOUNTING POLICIES AND OTHER RISKS AND UNCERTAINTIES (Details Narrative)
1 Months Ended 3 Months Ended 6 Months Ended
Aug. 31, 2026
USD ($)
$ / shares
Sep. 30, 2026
USD ($)
$ / shares
Sep. 30, 2025
Sep. 30, 2026
USD ($)
$ / shares
Sep. 30, 2025
USD ($)
Sep. 30, 2026
AUD ($)
Sep. 30, 2026
EUR (€)
Mar. 31, 2026
USD ($)
Product Information [Line Items]                
Issued and outstanding share capital | $ / shares $ 0.1999              
Percentage of outstanding equity awards | $ / shares 0.1999              
Exercise price of warrants | $ / shares $ 0.01 $ 10.66   $ 10.66        
Development and milestone payments receivable $ 32,500,000              
Commercial milestone payments amount 6,500,000              
Milestone payment amount $ 26,000,000.0              
Net cash used in operating activities       $ (10,514,000) $ (8,979,000)      
Accumulated deficit   $ 335,324,000   335,324,000       $ 319,571,000
Cash equivalents   13,700,000   13,700,000        
cash and cash equivalents held for sale   2,656,000   2,656,000      
Cash deposit   2,900,000   2,900,000        
Cash deposits   1,600,000   1,600,000        
Restricted cash   4,800,000   4,800,000       $ 5,600,000
Restricted account   $ 6,000,000.0   $ 6,000,000.0        
Concentration risk benchmark description       As of September 30, 2026, the Company had greater than $250,000 at United States financial institutions, less than A$250,000 at Australian financial institutions, greater than €100,000 at Irish financial institutions and also has funds on deposit in Israel.        
Accounts Payable [Member] | Customer Concentration Risk [Member] | Two Third Party Vendors [Member]                
Product Information [Line Items]                
Concentration percentage   97.00% 90.00% 96.00% 90.00%      
Accounts Payable [Member] | Customer Concentration Risk [Member] | First Third Party Vendor [Member]                
Product Information [Line Items]                
Concentration percentage   79.00% 71.00% 84.00% 66.00%      
Accounts Payable [Member] | Customer Concentration Risk [Member] | Second Third Party Vendor [Member]                
Product Information [Line Items]                
Concentration percentage   18.00% 19.00% 12.00% 24.00%      
Australian Taxation Office [Member]                
Product Information [Line Items]                
Tax Rebate       $ 0.0 $ 100,000      
UNITED STATES                
Product Information [Line Items]                
Cash FDIC insured amount   $ 250,000   250,000        
AUSTRALIA                
Product Information [Line Items]                
Cash FDIC insured amount           $ 250,000    
BERMUDA                
Product Information [Line Items]                
Cash FDIC insured amount   $ 25,000   $ 25,000        
IRELAND                
Product Information [Line Items]                
Cash FDIC insured amount | €             € 100,000  
CYPRUS                
Product Information [Line Items]                
Cash FDIC insured amount | €             € 100,000  
Beyond Cancer Ltd [Member]                
Product Information [Line Items]                
Subsidiary, Ownership Percentage, Noncontrolling Owner   20.00%   20.00%   20.00% 20.00%  
NeuroNOS Ltd [Member]                
Product Information [Line Items]                
Subsidiary, Ownership Percentage, Noncontrolling Owner   31.60%   31.60%   31.60% 31.60%